先进的一代疗法:用于瘤免疫治疗的生物模拟纳米输送系统
Jie Li1,2, Huamin Zeng3, Luwei Li4
1Center for Medicine Research and Translation, Chengdu Fifth People's Hospital (The Second Clinical Medical College, Affiliated Fifth People's Hospital of Chengdu University of Traditional Chinese Medicine), Chengdu 611135, Sichuan, China.
ACS nano
|December 6, 2023
概括
生物模拟纳米输送系统提供了一个有前途的策略,以提高瘤免疫疗法的有效性. 这些系统利用自然材料来改善治疗结果,并尽量减少癌症患者的副作用.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 纳米技术 纳米技术
- 生物材料是一种生物材料.
背景情况:
- 瘤免疫疗法是关键的精准医学策略,但由于免疫抑制性瘤微环境和异质性,通常会失败.
- 了解瘤免疫微环境和免疫逃生机制对于开发有效的癌症治疗至关重要.
研究的目的:
- 审查瘤及其免疫微环境之间的关系,以及瘤免疫逃生机制.
- 引入各种免疫疗法分类,并强调仿生纳米输送系统的作用.
- 讨论最近的进展,应用,挑战和生物模拟纳米输送系统在瘤免疫治疗中的未来前景.
主要方法:
- 文献综述和关于瘤免疫疗法和纳米输送系统的现有研究的摘要.
- 免疫疗法方法的分类,包括采用细胞疗法,细胞因子,癌症疫苗和免疫检查点抑制剂.
- 详细介绍利用免疫细胞,红细胞,瘤细胞,血小板和细菌的仿生纳米输送系统.
主要成果:
- 生物模拟纳米输送系统通过向瘤部位和减少非向效应,显示出提高免疫疗法疗效的潜力.
- 目前正在探索各种仿生材料,以提高药物输送和免疫反应调节的能力.
- 生物模拟纳米配送系统与瘤疫苗一起的具体应用也得到了审查.
结论:
- 生物模拟纳米输送系统在克服当前瘤免疫疗法的局限性方面取得了重大进展.
- 需要进一步的研究和开发来应对挑战,并充分实现这些系统在癌症治疗中的潜力.
相关概念视频
Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


